Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novo Nordisk will stop a trial studying Ozempic to treat kidney failure in patients with diabetes ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
The U.S. Food and Drug Administration (FDA) on Tuesday published letters warning two online vendors to stop selling unapproved versions of semaglutide and tirzepatide, the active ingredients in popular GLP-1 class medications including Novo Nordisk’s powerful weight-loss drug Wegovy. In the letters sent to Semaspace and Gorilla Healing on Oct. 2, the FDA said the only approved semaglutide products were Wegovy and Novo’s diabetes drugs Ozempic and Rybelsus.
Contract drug manufacturers seeking to tap into the booming market for weight-loss drugs are investing billions of dollars to expand or build factories that fill the injection pens used to administer treatments like Novo Nordisk's Wegovy. Interviews with a dozen company executives, analysts and investors showed pharmaceutical services companies jostling to secure more of the specialist work of filling the syringes used in the pens, a process known as fill-finish. "Every contract manufacturer that has sterile fill-finish capacity wants to add more, to get ahead, because it's no...
Medicines in the same class as Novo Nordisk's popular weight-loss therapy Wegovy may carry an increased risk of pancreatitis, intestinal blockage, and stomach paralysis compared to an older obesity...
Medicines in the same class as Novo Nordisk’s popular weight-loss therapy Wegovy may carry an increased risk of pancreatitis, intestinal blockage, and stomach paralysis compared to an older obesity drug, according to a study published on Thursday. For every 1,000 users of drugs with the same active ingredient as Wegovy, nearly five developed pancreatitis compared to one of every 1,000 users of bupropion-naltrexone, the active ingredients in the weight-loss drug Contrave, according to a report in the JAMA medical journal.